bioharvest.com - רווח החברה לפני מסים, ריבית ופחת BHST

Stable raw material harvesting at the Israeli bio-complex ensures high profitability for BioHarvest Sciences (BHST). The EBITDA volume visualizes current profit dynamics, where the 0.00 level indicates the parameter's status. Soil-less production in bioreactors guarantees scalability and margin growth. BioHarvest Sciences (BHST) is currently focusing on US expansion, the development of B2B supplies, and the conduct of therapeutic R&D research.

To objectively evaluate the issuer, a portfolio manager requires an analysis of the actual operating cash flow before depreciation and interest, which eliminates the impact of accounting adjustments. By tracking changes in EBITDA, the investor can discern the real cash efficiency of the business, which in the case of BioHarvest Sciences (BHST) confirms the high margins of B2B cellular ingredient supplies and the model's ability to generate high-quality free cash flow.